Literature DB >> 30355939

Inhibition of CXCR4 by MicroRNA-1192 Reduces the Activation of Th17 Cells and Expression of Inflammation Factors in a Mouse Model of Vulvovaginal Candidiasis.

Jing Liu1, Huai-Zhen Wang2, Yong Sun1.   

Abstract

BACKGROUND/AIMS: Vulvovaginal candidiasis (VVC) is a disease commonly occurring in sexually active women. The involvement of microRNAs in several kinds of infectious diseases has been highlighted in a number of researches. Therefore, we conducted the present study in order to investigate whether microRNA-1192 (miR-1192) would significantly target CXCR4 in Th17 cells as well as inflammatory factors in mouse models suffering from VVC.
METHODS: Seventy-five mice were selected as test subjects for this study, of which twenty-five were used as the normal control, while the rest were treated with estradiol or oil-treated in order to establish VVC mouse models (each n = 25). Protein expressions of CXCR4, IL-6, IL-17, and IL-23 were all measured using both an immunohistochemistry and ELISA. The Th17 cell percentage in peripheral blood and the expression of RORγt in Th17 cells were detected using a flow cytometry. Mouse vaginal epithelial cells were isolated from normal mice, after which the mice were treated with estradiol to regulate their estrogen, followed by treatments involving the miR-1192 mimic, miR-1192 inhibitor, siRNA-CXCR4, and miR-1192 inhibitor + si-CXCR4. The cell cycle, apoptosis, and proliferation were all examined by using an additional flow cytometry as well as the employment of the MTT assay. The miR-1192, CXCR4, IL-6, IL-17, and IL-23 expressions in tissues and cells were both measured using both RT-qPCR and western blot assay techniques.
RESULTS: The mice treated with either estradiol or oil had presented to us lowered levels in miR-1192 expression as well as higher levels in both Th17 cell percentage and expression of RORγt in Th17 cells, along with mRNA and protein expressions of CXCR4, IL-6, IL-17, and IL-23. In cell experiments, the mouse vaginal epithelial cells that had been treated with miR-1192 inhibitor had shown us a decreased cell proliferation rate and contrarily increased expressions of CXCR4, IL-6, IL-17, and IL-23 mRNA, protein, and cell apoptosis rate; these results were opposite to the ones found in the mice treated with miR-1192 mimic.
CONCLUSION: Our results provided significant evidence that miR-1192 could directly development and progression of VVC by restraining the CXCR4 gene in the VVC mice.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  CXCR4; Inflammation factors; MicroRNA-1192; Th17 cell; Vulvovaginal candidiasis

Mesh:

Substances:

Year:  2018        PMID: 30355939     DOI: 10.1159/000494475

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  5 in total

1.  Silencing of Long Noncoding RNA GAS5 Blocks Experimental Cerebral Ischemia-Reperfusion Injury by Restraining AQP4 Expression via the miR-1192/STAT5A Axis.

Authors:  Zhongzhong Jiang; Min Liu; Dezhi Huang; Yang Cai; Yu Zhou
Journal:  Mol Neurobiol       Date:  2022-10-05       Impact factor: 5.682

2.  Antifungal Effect of Long Noncoding RNA 9708-1 in the Vulvovaginal Candidiasis Murine Model.

Authors:  Ying Wu; Lisha Jiang; Lingling Zhang; Xia Liu; Lina Yan; Ting Luan; Can Rui; Zhiyuan Mao; Chong Fan; Yu Liu; Ping Li; Xin Zeng
Journal:  Mycopathologia       Date:  2021-02-15       Impact factor: 2.574

3.  Suppressed nuclear factor-kappa B alleviates lipopolysaccharide-induced acute lung injury through downregulation of CXCR4 mediated by microRNA-194.

Authors:  Ruidong Chen; Fei Xie; Jie Zhao; Bin Yue
Journal:  Respir Res       Date:  2020-06-10

4.  Association of IL-17 and IL-23 Gene Variants with Plasma Levels and Risk of Vulvovaginal Candidiasis in a Chinese Han Population.

Authors:  Wei Li; Wenyin Shi; Yujun Yin; Juan Chen; Lanlan Luo
Journal:  Pharmgenomics Pers Med       Date:  2020-12-15

5.  Long‑chain non‑coding RNA GAS5 promotes cell autophagy by modulating the miR‑181c‑5p/ATG5 and miR‑1192/ATG12 axes.

Authors:  Tao Xu; Xiangrong Xu; Yuankui Chu; Dan Jiang; Guangxian Xu
Journal:  Int J Mol Med       Date:  2021-10-05       Impact factor: 4.101

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.